問卷

TPIDB > Search Result > Clinical Trials List

Clinical Trials List

Protocol NumberC1071006
Active

2022-09-01 - 2028-12-31

Phase III

Recruiting4

xxxxxx

  • Sponsor

    xxxxxx

  • Trial scale

    Multi-Regional Multi-Center

  • Update

    2026/02/01

Investigators and Locations

Principal Investigator Shang-Yi Huang Division of Hematology & Oncology

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Recruiting

Principal Investigator Tung-Liang Lin Division of Hematology & Oncology

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Recruiting

Principal Investigator Su-Peng Yeh Division of Hematology & Oncology

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Recruiting

Principal Investigator CHENG-HSIEN LIN

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Recruiting

Condition/Disease

xxxxxx

Objectives

xxxxxx

Test Drug

xxxxxx

Active Ingredient

Elranatamab
Daratumumab
LENALIDOMIDE
DEXAMETHASONE

Dosage Form

270
270
130
110

Dosage

40mg/mL
1800mg/15mL
2.5mg/ 5 mg/ 10 mg/ 15 mg/ 20 mg/ 25 mg
4 mg/ 20 mg

Endpoints

xxxxxx

Inclution Criteria

xxxxxx

Exclusion Criteria

xxxxxx

The Estimated Number of Participants

  • Taiwan

    70 participants

  • Global

    1126 participants